A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease

计划入组 6,700 人 · 首次发布于 2026 年 9 月 16 日

Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers

计划入组 100 人 · 首次发布于 2026 年 7 月 7 日

Cognitive Neurology Unit Clinical Registry

计划入组 500 人 · 首次发布于 2023 年 6 月 29 日

Lecanemab(Leqembi)

Rx

Elezanumab

IMB-105

IRB Medical Equipment, LLC

United States

CT1812 Shows Promise in Alzheimer's Subgroup with Lower Tau Levels

Eisai Seeks FDA Approval for Subcutaneous LEQEMBI® in Alzheimer's Maintenance Therapy

Eisai Completes FDA Submission for Subcutaneous LEQEMBI® in Early Alzheimer's